Oxaliplatin is an antitumor drug that belongs to the third generation of platinum-based antitumor drugs. Oxaliplatin works in the same way as other platinum drugs, taking DNA as the target site of action, and platinum atoms form cross-linkages with DNA, which can antagonize DNA replication and transcription. Oxaliplatin can be combined with fluorouracil and has a synergistic effect. Clinically, oxaliplatin has relatively good efficacy in colorectal cancer and ovarian cancer, and also has some efficacy in gastric cancer, non-Hodgkin’s lymphoma, non-small cell lung cancer, and head and neck tumors. Oxaliplatin may also have some therapeutic effect on patients with colorectal cancer who are ineffective on fluorouracil therapy and resistant to other platinum-based drugs. In conclusion, oxaliplatin is an antitumor drug, which mainly exerts antitumor effects by inhibiting DNA replication and transcription.